Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Fourth Quarter Cash Dividend, Sets Fiscal 2018 Cash Dividend Rate, and Reaffirms Fiscal 2018 Guidance
GENERAL HIGHLIGHTS CINCINNATI, Nov. 09, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today: reported fourth quarter and full-year fiscal 2017 net revenues of $49.7 million and $200.8 million, respectively, increases of 6% and 2%, respectively, from the same periods of the prior fiscal year; reported fourth quarter operating income of $8.8 million (including $0.8 […]
Meridian Bioscience Comments on FDA Press Statement Regarding Its Warning Letter Issued to Magellan Diagnostics
CINCINNATI, Oct. 23, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that the FDA has issued a Warning Letter related to matters at its Magellan Diagnostics subsidiary. In our July 27, 2017 press release, Meridian indicated that it expected Magellan would receive a Warning Letter based on the observations from the FDA’s inspection, […]
Meridian Bioscience, Inc. Comments on Preliminary Fiscal 2017 Operating Results and Provides Fiscal 2018 Revenue and Earnings Guidance
CINCINNATI, Oct. 19, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that based on preliminary results, it expects revenues for fiscal 2017, ended on September 30, 2017, to be approximately $200.5 million, an increase of 2% compared to the prior year. Diluted earnings per share on a GAAP basis are expected to be […]
Meridian Bioscience, Inc. Expects to Report Fiscal 2018 Revenue and Earnings Guidance on Thursday, October 19, 2017
CINCINNATI, Oct. 16, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO), a leading diagnostic and life science component company, expects to release its fiscal 2018 Revenue and Earnings Guidance before the NASDAQ market opens on Thursday, October 19. The release will be available shortly thereafter on Meridian’s website at www.meridianbioscience.com. About Meridian Bioscience, Inc. Meridian is […]
Meridian Bioscience, Inc. Appoints Jack Kenny as Chief Executive Officer
CINCINNATI, Oct. 10, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has appointed John (Jack) P. Kenny as Chief Executive Officer, effective October 9, 2017. This addition to Meridian’s management team is consistent with the succession planning described in our May 10, 2017 press release. Mr. Kenny joins Meridian after a […]
Meridian Contributes to Upcoming “LEADCON 2017” – Third Annual International Conference on the Prevention of Lead and Heavy Metal Toxicity in Hyderabad, India
Company to share perspectives on the role that point-of-care screening for lead exposure can play in improving human health CINCINNATI, Sept. 19, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that Magellan Diagnostics, Inc., a business unit of Meridian, will support and participate in an international conference on the impacts of lead and […]
Meridian Launches TRU Block® ULTRA – A Powerful Immunoassay Interference Blocker
CINCINNATI, Sept. 05, 2017 (GLOBE NEWSWIRE) — Meridian Life Science, Inc., (MLS) of Memphis, Tennessee, a wholly-owned subsidiary of Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the launch of TRU Block® ULTRA. This product is the result of years of R&D aimed at creating the most powerful immunoassay interference blocker in the market. The advantage of TRU […]
Meridian Initiates Clinical Trials for New Neonatal Saliva CMV illumigene Test
CINCINNATI, Aug. 09, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that it has initiated clinical trials for a new illumigene CMV molecular amplification test. This assay is designed to specifically detect the congenital Cytomegalovirus (CMV) infection in newborns from saliva. Presently, there is no FDA-cleared test for CMV screening in newborns. Meridian has enrolled an […]
Meridian Bioscience Introduces the Expansion of Its ImmunoCard STAT!® Product Line
CINCINNATI, Aug. 08, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced the expansion of its ImmunoCard STAT!® product line with the addition of ImmunoCard STAT! FLU A&B. The ImmunoCard STAT! FLU A&B product is CLIA waived and meets the new FDA reclassification requirements. ImmunoCard STAT! FLU A&B detects the presence of influenza A & B in nasal and […]
Meridian Bioscience Elects John Rice to the Board of Directors
CINCINNATI, Aug. 08, 2017 (GLOBE NEWSWIRE) — Meridian Bioscience, Inc. (NASDAQ:VIVO) today announced that its Board of Directors elected a new independent director, John M. Rice, Ph.D., effective August 8, 2017. Mr. Rice is the founder, and since 2003 has been the Managing Partner, of Triathlon Medical Venture Partners, a venture capital firm that invests […]